

# Cost-Effectiveness of Noninvasive Liver Fibrosis Tests for Treatment Decisions in Patients With Chronic Hepatitis C

Emmanuel A. Tsochatzis,<sup>1\*</sup> Catriona Crossan,<sup>2\*</sup> Louise Longworth,<sup>2</sup> Kurinchi Gurusamy,<sup>3</sup> Manolo Rodriguez-Peralvarez,<sup>1</sup> Konstantinos Mantzoukis,<sup>1</sup> Julia O'Brien,<sup>1</sup> Evangelos Thalassinou,<sup>1</sup> Vassilios Papastergiou,<sup>1</sup> Anna Noel-Storr,<sup>4</sup> Brian Davidson,<sup>3</sup> and Andrew K Burroughs<sup>1</sup>

The cost-effectiveness of noninvasive tests (NITs) as alternatives to liver biopsy is unknown. We compared the cost-effectiveness of using NITs to inform treatment decisions in adult patients with chronic hepatitis C (CHC). We conducted a systematic review and meta-analysis to calculate the diagnostic accuracy of various NITs using a bivariate random-effects model. We constructed a probabilistic decision analytical model to estimate health care costs and outcomes (quality-adjusted life-years; QALYs) using data from the meta-analysis, literature, and national UK data. We compared the cost-effectiveness of four treatment strategies: testing with NITs and treating patients with fibrosis stage  $\geq$ F2; testing with liver biopsy and treating patients with  $\geq$ F2; treat none; and treat all irrespective of fibrosis. We compared all NITs and tested the cost-effectiveness using current triple therapy with boceprevir or telaprevir, but also modeled new, more-potent antivirals. Treating all patients without any previous NIT was the most effective strategy and had an incremental cost-effectiveness ratio (ICER) of £9,204 per additional QALY gained. The exploratory analysis of currently licensed sofosbuvir treatment regimens found that treat all was cost-effective, compared to using an NIT to decide on treatment, with an ICER of £16,028 per QALY gained. The exploratory analysis to assess the possible effect on results of new treatments, found that if SVR rates increased to  $>90\%$  for genotypes 1-4, the incremental treatment cost threshold for the “treat all” strategy to remain the most cost-effective strategy would be £37,500. Above this threshold, the most cost-effective option would be noninvasive testing with magnetic resonance elastography (ICER = £9,189). **Conclusions:** Treating all adult patients with CHC, irrespective of fibrosis stage, is the most cost-effective strategy with currently available drugs in developed countries. (HEPATOLOGY 2014;00:000-000)

Chronic hepatitis C (CHC) virus infection is one of the main causes of chronic liver disease, with an estimated 130-170 million persons infected worldwide. The natural history of the disease is variable, and it is estimated that one third of infected patients will progress to cirrhosis in less than 20 years, whereas another one third will never progress to cirrhosis.<sup>1</sup> Antiviral treatment can eradicate the virus

Abbreviations: AEs, adverse events; APRI, aspartate transaminase to platelets ratio index; BOC, boceprevir; CEAFs, cost-effectiveness acceptability frontiers; CHC, chronic hepatitis C; FN, false negative; FP, false positive; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HTA, Health Technology Assessment; ICER, incremental cost-effectiveness ratio; IFN, interferon; LT, liver transplantation; MRE, magnetic resonance elastography; NICE, National Institute for Health and Clinical Excellence; NITs, noninvasive tests; Peg-IFN, pegylated IFN; PA, probabilistic sensitivity analysis; QALYs, quality-adjusted life-years; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; TN, true negative; TP, true positive; TT, triple therapy; TVR, telaprevir.

From the <sup>1</sup>Sheila Sherlock Liver Unit and UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK; <sup>2</sup>Health Economics Research Group, Brunel University, Uxbridge, UK; <sup>3</sup>Royal Free Campus, UCL Medical School, London, UK; <sup>4</sup>Cochrane Dementia and Cognitive Improvement Group, Nuffield Department of Medicine, Oxford University, Oxford, UK.

Received February 24, 2014; accepted June 27, 2014.

This project was funded by the National Institute for Health Research Health Technology Assessment program (HTA project 09/114/02) and will be published in full in the Health Technology Assessment journal series. Visit the HTA program website for more details ([www.hta.ac.uk/link](http://www.hta.ac.uk/link) to project page). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health.

\*These two authors contributed equally to this work and are joint first authors.

and stop further fibrosis progression. With current antiviral treatment, sustained virological response (SVR) rates are 75% for genotype 1 and 80% for genotypes 2 and 3.<sup>2</sup> These rates are going to further increase in the next 5 years, because more-effective antivirals are being developed.

There has always been a dilemma concerning which patients to treat, because interferon (IFN)-based treatments have considerable side effects and not all patients with CHC will progress to cirrhosis. Indeed, antiviral treatment has been advocated for patients with fibrosis stage  $\geq$ F2, whereas those with less fibrosis could potentially wait.<sup>3</sup> A caveat to this strategy was the need for liver biopsy in order to assess the extent of fibrosis. Therefore, clinical practice evolved to treat most patients with antiviral treatment without a liver biopsy, irrespective of fibrosis stage.

The recent explosive development and use of noninvasive tests (NITs) for evaluating fibrosis has led to questioning this approach, particularly because more effective treatments with fewer side effects will soon become available and thus patients can potentially wait. Moreover, because NITs can be performed serially in the same patient and therefore the evolution of fibrosis can be monitored, this newer paradigm is used more often. Therefore, the use of NITs before deciding to start antiviral therapy might be a more cost-effective approach given the increased costs of new therapies.<sup>4</sup> In the current study, we assessed the cost-effectiveness of such tests for treatment decisions in adult patients with CHC.

## Materials and Methods

**Systematic Review.** We performed a systematic review and meta-analysis to determine the diagnostic accuracy of NITs, compared to liver biopsy, in adult patients with CHC. This was part of a larger project funded by the UK National Institute for Health Research Health Technology Assessment Program that determined the cost-effectiveness of NITs in patients with hepatitis B virus, hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic fatty liver disease. The study is registered in the PROSPERO database (PROSPERO 2011:CRD42011001561).

**Study Selection and Data Extraction.** MEDLINE, Embase, and Science Citation Index Expanded were searched from 1988 until April 2012 for all available studies of NITs across all etiologies of liver disease as part of the larger project. Studies that reported on patients with HCV were selected and included for this article. Reference lists of identified studies and reviews and conference proceedings from recent hepatology conferences (last 2 years) were hand searched to identify further studies. The search strategy is provided in the Web Appendix (see the Supporting Information).

We included full articles and abstracts, which provided the data necessary to determine the number of true positive (TP), true negative (TN), false positive (FP), and false negative (FN) results of the NITs for  $\geq$ F2 using liver biopsy as the reference standard, irrespective of language or publication status. We excluded studies that reported on fewer than 10 patients and when the maximum interval between liver biopsy and the NITs was  $>$ 6 months.

Study selection and data extraction were performed independently by two researchers. Data were entered into a specifically created Excel file. The quality of the included studies was assessed independently by two researchers using the QUADAS-2 tool.<sup>5</sup> The criteria used for QUADAS-2 assessment are shown in the Web Appendix (see the Supporting Information).

**Data Analysis.** The data were combined using the bivariate random-effects model,<sup>6</sup> with correlation between sensitivity and specificity using the META-DAS macro developed by the SRDTA Working Group in the SAS 9.2 statistical software (SAS Institute Inc., Cary, NC).<sup>7</sup> For tests with explicit thresholds, such as serum markers, we calculated the summary sensitivity and specificity at specific thresholds. If the results did not converge using the above-mentioned random-effects model with a correlation between sensitivity and specificity, we performed the meta-analysis with variations of bivariate analysis, which included bivariate random-effects model without correlation, fixed-effect model for sensitivity and random-effects model for specificity, random-effects model for sensitivity and fixed-effect model for specificity, and fixed-effects model for both sensitivity and specificity, depending

---

Address reprint requests to: Emmanuel A. Tsochatzis, M.D., Ph.D., The Royal Free Sheila Sherlock Liver Center and UCL Institute for Liver and Digestive Health, The Royal Free Hospital, Pond Street London NW3 2QG, UK. E-mail: e.tsochatzis@ucl.ac.uk; fax: +44-20-74726226.

Copyright © 2014 The Authors. HEPATOLOGY published by Wiley on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).

DOI 10.1002/hep.27296

Potential conflict of interest: Nothing to report.

**Table 1. Sequential Testing Approach: Hepatitis C Model**

	First NIT Result		Second NIT Result	
	Positive	Negative	Positive	Negative
Strategy 1	Treat patients	Liver biopsy		
Strategy 2	Do second test	Watchful waiting	Treat patients	Liver biopsy
Strategy 3	Do second test	Liver biopsy	Treat patients	Liver biopsy
Perform two NITs regardless of test outcome				
Strategy 4	Agree (+): treat Agree (-): watchful waiting		Agree: treat or watchful waiting Disagree: liver biopsy	

upon the distribution of sensitivities and specificities across the studies. We also calculated the median, lowest, and highest prevalence for the specific stages of fibrosis in the included studies.

**Economic Evaluation: Approach to Analysis.** The systematic review identified 57 relevant NITs for use in CHC. We assessed the cost-effectiveness of the NITs in the context of treating patients with fibrosis stage  $\geq$ F2. Additional comparators for the strategies including NITs were: (1) treat all patients with CHC irrespective of fibrosis; (2) treat none; and (3) biopsy all and treat those with fibrosis stage  $\geq$ F2.

We initially conducted an analysis where we compared single NITs to each other. We assumed that only patients who tested positive (TP or FP) would receive immediate treatment with anti-viral agents. We then conducted a second analysis, which evaluated the use of more than one test, combined based on four sequential test strategies which are or could potentially be used in clinical practice (see Table 1). Given the large number of tests, it was not feasible to model combinations of all identified NITs; therefore, we chose six NITs from within three defined test categories (indirect serum markers, direct and patented serum markers, and imaging modalities). To choose the six NITs, we used a decision rule whereby we chose the best NIT (defined as the most cost-effective NIT at a cost-effectiveness threshold of £20,000) from within each category with a defined diagnostic cutoff (high or low) and the best NIT without any defined cut-off. We assumed that NITs used sequentially were independent of each other.

The second analysis compared the six chosen NITs used singly, combinations of the six NITs based on the four sequential testing strategies (Table 1), liver biopsy, “treat all” and “treat no one,” four published algorithms for CHC (SAFE, Fibropaca, Bordeaux, and Leroy), which are a combination of NITs used sequentially or concomitantly, and several NITs with a dual diagnostic threshold (a high cutoff with high specificity and a low cutoff with high sensitivity; when these cutoffs are combined to minimize the number of FPs and

FNs, then a number of patients falling between the two cutoffs have indeterminate results and need further testing), resulting in a comparison of 56 strategies in the second analysis.

**Model Structure.** The analyses were based on a decision tree, combined with a Markov model to estimate the long-term costs and outcomes associated with each potential NIT diagnosis: TP, FP, FN, or TN and the treat all and treat no one testing strategies. The Markov model estimated the lifetime mean costs and outcomes for a hypothetical cohort of 1,000 patients with CHC genotypes 1-4, with suspected fibrosis, who would usually present for liver biopsy. The model structure is a modified version of previously published models of liver fibrosis in CHC (Fig. 1).<sup>8,9</sup> We validated the model natural history outputs using data from a study that retrospectively assessed a cohort of patients who did not attain SVR after IFN treatment<sup>10</sup>; the outputs were similar for patients with F4.

Health outcomes were expressed as quality-adjusted life-years (QALYs), which combine data on life expectancy with data reflecting quality of life (sometimes referred to as “utility” data). The study was carried out from a UK National Health Service perspective. A threshold value for incremental cost-effectiveness was assumed to be £20,000 per additional QALY gained, based on the lower boundary of UK guidelines, and was varied in sensitivity analysis.<sup>11</sup> A discount rate of 3.5% was applied to costs and QALYs.<sup>11</sup> The decision tree was populated with results from the Markov model, summary sensitivity and specificity, and average disease prevalence to estimate the cost-effectiveness of all comparators.

**Input Parameters.** The disease prevalence for the F0-F1, F2-F3, and F4 health states as well as the diagnostic accuracy of the NITs were estimated using data from the systematic literature review.

In accord with UK national guidelines, treatment reflected in the model was a combination of pegylated IFN (Peg-IFN)- $\alpha$ -2a or - $\alpha$ -2b, ribavirin (RBV), and telaprevir (TVR) or boceprevir (BOC), depending upon the genotype.<sup>12-15</sup> Genotype 1 patients received triple therapy (TT) with BOC or TVR (50/50 split).




Fig. 1. Illustration of the Markov model used for economic analysis. The disease stages reflect the Metavir staging score for liver fibrosis and cirrhosis. The cohort represents those suspected of liver fibrosis who can enter the models in one of three disease stages: mild fibrosis (Metavir stages F0-F1), moderate fibrosis (Metavir stages F2-F3), and compensated cirrhosis (Metavir stage F4), with the proportions determined by the prevalence estimated from the results of the systematic review (prevalence  $\geq$ F2: 53%). Within the model, patients can remain within any disease stage for longer than one cycle (length of cycle is set as 1 year), except for the LT disease stage, where patients can only progress to either a post-LT stage or death.

Treatment was initiated if the diagnostic test result (from the NITs used singly or in combination) was equal to a Metavir score of moderate fibrosis ( $\geq$ F2; TP and FP). Otherwise, a strategy of “watchful waiting” was initiated whereby patients would be retested with a NIT every 2 years. The effect of treatment in the model was based on SVR rates, such that if patients achieved SVR, they no longer retained the risk of progression to a worse disease stage and reverted to general population mortality rates.

The rate of disease progression in the Markov model was sourced from a published cost-effectiveness study by Wright et al.<sup>9</sup>; early disease stage costs ( $\leq$ F4) and health-related utility data were also sourced from this study; as per National Institute for Health and Clinical Excellence (NICE) guidance,<sup>11</sup> the data were based on patients’ self-reported health status using the EQ-5D questionnaire in a UK population.<sup>16</sup> Later disease stage costs and utilities were estimated using the raw data from a cost-effectiveness study of liver transplantation (LT).<sup>17</sup> We incorporated adverse effects (AEs) associated with Peg-IFN- $\alpha$  treatment in the model by applying a disutility during treatment, using data from Wright et al.<sup>9</sup> We allowed for an increased EQ-5D value post-successful response (SVR) to treatment.<sup>9</sup>

Cohort characteristics, mortality data, SVR rates after treatment, and treatment costs were sourced from

published literature and routine national UK source of cost data. All input parameters and sources are listed in Table 2. Costs for the NITs and liver biopsy are listed in the Web Appendix (see the Supporting Information).

**Analysis of Results and Uncertainty.** We conducted an incremental analysis to identify the cost-effective testing strategy.<sup>18</sup> We ruled out test strategies, which were more costly and less effective (“dominated”). We then estimated incremental cost-effectiveness ratios (ICERs), for the remaining NITs, where they were compared to the next-best alternative, calculated using the formula:

$$\text{ICER} = ((C_1 - C_0)/(E_1 - E_0))$$

where  $C_1$  = lifetime cost of strategy 1,  $C_0$  = lifetime cost of (the next-best) strategy,  $E_1$  = QALYs from strategy 1 and, and  $E_0$  = QALYs from (the next-best) strategy.

Test strategies with an ICER greater than that of a more-effective intervention (extendedly dominated) were also ruled out, and the remaining tests were then compared to identify the NIT leading to the highest QALY gain given a £20,000/QALY cost-effectiveness threshold.

Probabilistic sensitivity analysis (PSA) was used to represent uncertainty in the model, and cost-effectiveness acceptability frontiers (CEAFs) were

**Table 2. Input Parameters: Hepatitis C Model**

Model Inputs	Parameters Value	PSA distribution (if applicable)	Source		
Cohort characteristics					
Age	40		Wright et al. <sup>27</sup>		
Average weight	79.8 kg		Fried et al. <sup>28</sup>		
% male	61		Wright et al. <sup>27</sup>		
Genotype, %					
1	66				
2 and 3	31		Fried et al. <sup>28</sup>		
4	3				
Natural history data					
Mild-moderate fibrosis	0.025	Dirichlet	Wright et al. <sup>27</sup>		
Moderate fibrosis-compensated cirrhosis	0.037				
Cirrhosis-decompensated cirrhosis	0.04				
Cirrhosis-HCC	0.14				
Decompensated cirrhosis/HCC-LT	0.02				
Decompensated cirrhosis-death	0.13				
HCC-death	0.43				
LT-Death	0.15				
Post-LT-death	0.03				
All-cause mortality	Range from 0.014 to 0.335		Interim life table England and Wales, 2008-2010		
<b>SVR Rate</b>					
	Treatment	Dosage (mg)	Duration (weeks)	SVR Rate (%)	Source
Genotype 1: treatment naïve	Peg-IFN- $\alpha$ -2a	180 (weekly)	48		NICE HTA 252 <sup>13</sup>
	RBV	1,200 (daily)	48	75	
	TVR	2,250 (daily)	12		
Genotype 1: treatment naïve	Peg-IFN- $\alpha$ -2b	120 (weekly)	48		NICE HTA 253 <sup>12</sup>
	RBV	1,000 (daily)	48	66.1	
	BOC	2,400 (daily)	32		
Genotype 1: patients with cirrhosis (treatment naïve)	Peg-IFN- $\alpha$ -2b	120 (weekly)	48		NICE HTA 253 <sup>12</sup>
	RBV	1,000 (daily)	48	41.7	
	BOC	2,400 (daily)	36		
Genotypes 2 and 3 (treatment naïve)	Peg-IFN- $\alpha$ -2a	180 (weekly)	24	76	Fried et al. <sup>28</sup>
	RBV	1,200 (daily)	24		
	Peg-IFN- $\alpha$ -2b	120 (weekly)	24	82	Manns et al. <sup>29</sup>
	RBV	1,000 (daily)	24		
Genotype 4 (treatment naïve)	Peg-IFN- $\alpha$ -2a	180 (weekly)	48	77	Fried et al. <sup>28</sup>
	RBV	1,200 (daily)	48		
	Peg-IFN- $\alpha$ -2b	120 (weekly)	48	69	Kamal et al. <sup>30</sup>
	RBV	1,000 (daily)	48		
<b>Health State Costs</b>					
	Mean	Standard Error	PSA Distribution	Source	
Mild fibrosis	185	36.39		Wright et al. <sup>27</sup>	
Moderate fibrosis	959	101.69	Gamma		
Compensated cirrhosis	1,521	309.05			
Decompensated cirrhosis	38,871	9410.46		Longworth et al. <sup>17</sup>	

Table 2. Continued

Health State Costs				
	Mean	Standard Error	PSA Distribution	Source
HCC	38,871	9410.46		
LT	69,174	7054.86		
Post-LT	4,356	861.57		
Treatment Costs				
	Treatment	Cost		Source
Genotype 1: treatment naïve	Peg-IFN- $\alpha$ -2a and RBV/TVR	32,809		British National Formulary 64
Genotype 1: treatment naïve	Peg-IFN- $\alpha$ -2b and RBV/BOC	33,270		<a href="http://www.bnf.org/bnf/index.htm">http://www.bnf.org/bnf/index.htm</a>
Genotype 1: patients with cirrhosis	Peg-IFN- $\alpha$ -2b and RBV/BOC	41,670		
Genotypes 2 and 3	Peg-IFN- $\alpha$ -2a and RBV	4,446		
Genotypes 2 and 3	Peg-IFN- $\alpha$ -2b and RBV	5,435		
Genotype 4	Peg-IFN- $\alpha$ -2a and RBV	10,411		
Genotype 4	Peg-IFN- $\alpha$ -2b and RBV	10,870		
Utilities				
	Mean	Standard Error	PSA Distribution	Source
Without treatment with antiviral agents				
Mild fibrosis	0.77	0.035	Beta	Wright et al. <sup>27</sup>
Moderate fibrosis	0.66	0.018		
Compensated cirrhosis	0.55	0.032		
Decompensated cirrhosis	0.49	0.056		Longworth et al. <sup>17</sup>
HCC	0.49	0.056		
LT	0.51	0.053		
Post-LT	0.52	0.061		
Death	0	0		
During treatment with antiviral agents				
Mild fibrosis (during treatment)	0.65	0.035	Beta	Wright et al. <sup>27</sup>
Moderate fibrosis (during treatment)	0.55	0.018		
Compensated cirrhosis (during treatment)	0.44	0.04		Grishchenko et al. <sup>31</sup>
After successful response to treatment with antiviral agents				
Mild fibrosis (SVR after treatment)	0.82	0.04	Beta	Wright et al. <sup>27</sup>
Moderate fibrosis (SVR after treatment)	0.71	0.05		
Compensated cirrhosis (SVR after treatment)	0.60	0.04		Grishchenko et al. <sup>31</sup>

constructed. The CEAF plots the uncertainty associated with the optimal testing strategy, for different values of the cost-effectiveness threshold (threshold value range varied from £0 to £60,000).<sup>19</sup>

**Sensitivity Analysis.** A number of one-way sensitivity analyses were conducted in order to test the robustness of our findings.

1. We assumed that there was no increase in utility values after a successful response (represented by SVR in the model) to treatment with antiviral agents.
2. We assumed that there was no reduction in utility values during treatment with antiviral agents.
3. We assumed an additional disutility decrement value of 0.05 to represent potential AEs from the use of TVR or BOC in HCV genotype 1 patients.
4. We used higher utility values for all health states. These values were sourced from a published *Health Technology Assessment* (HTA) report.<sup>20</sup>
5. We changed the prevalence of  $\geq$ F2 disease (53%) to the minimum and maximum estimates extracted from the meta-analysis (17% and 83%, respectively).
6. The base-case model assumes that patients with no or mild fibrosis who are treated incorrectly (test diagnosis of FP) benefit from antiviral treatment. We tested this assumption by reducing the successful response to treatment (SVR rate) for this group of patients by decrements of 10%.
7. We conducted an analysis allowing for patients in a cirrhotic health state who had a successful response to treatment (SVR) to retain a small risk of progression to decompensated cirrhosis (0.4%) and hepatocellular carcinoma (HCC; 0.2%) health states.
8. Our base-case analysis assumes that the retest (from the meta-analysis of the systematic review data in the watchful waiting strategy for patients with a negative test result) correctly identified all patients who had progressed to a health state

$\geq$ F2. We tested this assumption by applying the sensitivity and specificity of three commonly used tests (aspartate transaminase to platelets ratio index [APRI], FibroTest, and FibroScan).

9. We assumed a later starting age (50 years) in the model by amending the rates of all-cause mortality to reflect a cohort of  $\geq$ 50 years. We also increased the probability of disease progression in the mild and moderate health states to reflect those of an older cohort of patients (transition probability of 0.067 and 0.077 to reflect progression from a mild to moderate health state from a moderate to cirrhotic health state, respectively).
10. We incorporated a discontinuation rate for TT with BOC or TVR, which had an effect on the total cost of treatment. The discontinuation rates for BOC were 4% at week 12 and 2% at week 24 and for TVR 5% at week 4 and 2% at week 12.<sup>13,14</sup>

**Secondary Analysis.** Summary sensitivity and specificity estimates for some of the NITs were based on only one study. Taking this into consideration, we conducted a secondary analysis where we evaluated only those NITs (14 NITs) where the bivariate model for the meta-analysis converged (used as an indicator of the magnitude of the evidence base underlying an NIT).

**Exploratory Analysis.** We conducted an exploratory analysis to assess the potential effect of new therapies on the findings for NITs. We assessed the effect of increased treatment costs and effectiveness to reflect the use of sofosbuvir (SOF) as part of TT in combination with Peg-IFN- $\alpha$ -2a/2b and RBV. We assumed that genotype 1 and 4 patients would receive treatment with Peg-IFN- $\alpha$ -2a, RBV, and SOF for a total of 12 weeks (SVR rate: 89% and 96%, respectively, with a total treatment cost of £36,476). We assumed that genotype 2 patients would receive treatment with RBV and SOF for a total of 12 weeks (SVR rate without cirrhosis: 92%; SVR rate with cirrhosis: 94%; with a total treatment cost of £35,723). We assumed that genotype 3 patients would receive treatment with RBV and SOF for a total of 24 weeks (SVR rate without cirrhosis: 94%; SVR rate with cirrhosis: 92%; with a total treatment cost of £71,466).<sup>21</sup>

We further assessed potential new IFN-free therapies with assuming an SVR rate of 90% for genotype 1, 92% for genotypes 2 and 3, and 94% for genotype 4.

## Results

**Meta-Analysis.** The selection flow chart for studies is shown in Fig. 1 (Web Appendix in the Supporting Information). Data on patients with HCV were

extracted from 162 studies (Web Appendix in the Supporting Information). NIT cutoffs for the diagnosis of specific histological stages were not always predetermined and, consequently, varied. Cutoffs were grouped into narrow ranges, as appropriate. Therefore, when a range of cutoffs is mentioned in the results tables (Table 3), the reported sensitivities and specificities are probably overestimated.

A number of mainly indirect NITs reported sensitivities and specificities at dual cutoffs, one high and one low. The low and high cut-off threshold is usually set at 90%-95% of sensitivity and specificity, respectively. We performed separate meta-analyses of low and high cutoffs whenever such cutoffs were reported.

The most commonly evaluated NITs for  $\geq$ F2 were APRI (low cutoff), which was evaluated in 47 studies, followed by FibroScan in 37 studies and APRI (high cutoff) in 36 studies. Summary sensitivity and specificity of NITs for diagnosis of  $\geq$ F2 is shown in Table 3. Overall, only five studies had low risk of bias in all the domains of the QUADAS-2 tool; therefore, all our estimates may be biased. A table of the quality assessment of included studies based on QUADAS-2 is in the Web Appendix (see the Supporting Information).

**Economic Modeling.** The most cost-effective strategy is to adopt a treat all approach with an ICER of £9,204. This ICER reflects that the treat all strategy has a QALY gain of 0.47 at an additional cost of £4,287, compared to the next-best alternative (FibroSpect and FibroScan) and is within the standard UK threshold range for cost-effectiveness. Table 4 displays results of the base-case analysis (second stage of the analyses); for clarity of presentation, only test strategies that were not “dominated” or “extendedly dominated” are shown in the table (see the Web Appendix in the Supporting Information for full table and results of the comparison of NITs evaluated as single tests). The CEAF (Fig. 2) shows that the probability of treat all being cost-effective, given a cost-effectiveness threshold value of £20,000, is 45%.

**Sensitivity Analyses.** The base-case analysis result remained robust to the majority of the sensitivity analyses. Analyses that changed the base-case result are detailed below.

Amending the assumption that patients who were treated incorrectly (patients with mild fibrosis [F0-F1] who test FP), benefitted from treatment, changed the base-case results. We reduced the SVR rate (representative of treatment benefit) for these patients by decrements of 10%. When the SVR rate was reduced by more than 23%, treat all was no longer cost-effective. The illustrative graph (see Fig. 2 in the Web Appendix

**Table 3. Diagnostic Accuracy of NITs for Detection of Fibrosis Stage  $\geq$ F2 in Patients With CHC**

Test	Number of Studies	Cutoff	Summary Sensitivity	95% CI	Summary Specificity	95% CI	Statistics
Indirect noninvasive serum tests							
APRI (low cutoff)	47	0.4-0.7	0.82	0.77-0.86	0.57	0.49-0.65	Bivariate random-effects model with correlation between sensitivity and specificity
APRI (high cutoff)	36	1.5	0.39	0.32-0.47	0.92	0.89-0.95	Bivariate random-effects model with correlation between sensitivity and specificity
Age_Platelet index	1	3	0.58	0.46-0.70	0.70	0.64-0.84	Single study
AST_ALT_ratio	7	0.6-1	0.44	0.27-0.63	0.71	0.62-0.78	Bivariate random-effects model with correlation between sensitivity and specificity
Cirrhosis discriminant score	1	6	0.66	0.59-0.73	0.49	0.34-0.64	Single study
FIB-4 (low cutoff)	11	0.6-1.45	0.89	0.79-0.95	0.42	0.25-0.61	Random-effects model for sensitivity and specificity without correlation
FIB-4 (high cutoff)	9	1-3.25	0.59	0.43-0.73	0.74	0.56-0.87	Bivariate random-effects model with correlation between sensitivity and specificity
Forns index (low cutoff)	18	4.2-4.5	0.88	0.83-0.91	0.40	0.33-0.48	Bivariate random-effects model with correlation between sensitivity and specificity
Forns index (high cutoff)	15	6.9-8.7	0.35	0.29-0.41	0.96	0.92-0.98	Bivariate random-effects model with correlation between sensitivity and specificity
FibroQ	1	1.6	0.78	0.71-0.83	0.66	0.51-0.78	Single study
Fibrosis probability index (low cutoff)	2	0.2	0.91	0.83-0.96	0.45	0.34-0.57	Fixed-effects model for sensitivity and specificity without correlation
Fibrosis probability index (high cutoff)	2	0.8	0.42	0.32-0.54	0.95	0.87-0.98	Fixed-effects model for sensitivity and specificity without correlation
GUCI	3	0.33-1.1	0.65	0.1-1.00	0.79	0.03-1.00	Bivariate random-effects model with correlation between sensitivity and specificity
Kings	1	9.87	0.84	0.75-0.9	0.70	0.61-0.79	Single study
Kings (low cutoff)	1	4.46	0.62	0.55-0.69	0.81	0.76-0.86	Single study
Kings (high cutoff)	1	12.3	0.58	0.51-0.65	0.79	0.73-0.83	Single study
Lok's model	4	0.2-1.67	0.67	0.55-0.77	0.55	0.29-0.78	Bivariate random-effects model with correlation between sensitivity and specificity
Platelets	10	48-182	0.50	0.41-0.59	0.89	0.83-0.93	Bivariate random-effects model with correlation between sensitivity and specificity
Pohl index	2	Positive	0.06	0.04-0.1	0.99	0.93-1.00	Fixed-effects model for sensitivity and specificity without correlation
Direct serum noninvasive serum tests							
Aminopyrine breath test	1	8.1	0.73	0.57-0.85	0.74	0.58-0.85	Single study
Hyaluronic acid	8	34-110 ng/mL	0.75	0.64-0.83	0.75	0.68-0.82	Bivariate random-effects model with correlation between sensitivity and specificity
Hepascore	10	0.31-0.5	0.73	0.66-0.79	0.73	0.65-0.79	Bivariate random-effects model with correlation between sensitivity and specificity
Hepascore (high cutoff)	1	0.84	0.33	0.24-0.43	0.92	0.85-0.96	Single study
MP3	1	0.3	0.82	0.73-0.89	0.73	0.63-0.81	Single study
PIIINP	2	8.3-9.1	0.78	0.63-0.87	0.76	0.54-0.90	Fixed-effects model for sensitivity and specificity without correlation
PIIINP/MMP-1 index	1	0.3	0.65	0.55-0.75	0.85	0.77-0.90	Single study
Type IV collagen	5	110-298	0.88	0.71-0.96	0.73	0.63-0.82	Random-effects model for sensitivity and specificity without correlation
YKL-40 (low cutoff)	1	290	0.80	0.66-0.89	0.33	0.26-0.41	Single study
YKL-40 (high cutoff)	1	540	0.33	0.21-0.48	0.80	0.73-0.86	Single study
Commercial noninvasive serum tests							
ELF	1	8.75	0.84	0.69-0.92	0.70	0.52-0.83	Single study
ELF (low cutoff)	1	9.55	0.90	0.85-0.93	0.52	0.43-0.61	Single study

Table 3. Continued

Test	Number of Studies	Cutoff	Summary Sensitivity	95% CI	Summary Specificity	95% CI	Statistics
ELF (high cutoff)	1	11.07	0.47	0.41-0.54	0.90	0.83-0.94	Single study
FibroIndex (low cutoff)	4	1.25	0.83	0.15-0.99	0.57	0.22-0.86	Random-effects model for sensitivity and specificity without correlation
FibroIndex (high cutoff)	4	2.25	0.24	0.11-0.43	0.98	0.93-1.00	Random-effects model for sensitivity and fixed-effect model for specificity without correlation
FibroMeter	4	0.42-0.57	0.79	0.69-0.86	0.73	0.63-0.81	Bivariate random-effects model with correlation between sensitivity and specificity
FibroSpect II	5	42-72	0.78	0.49-0.93	0.71	0.59-0.80	Random-effects model for sensitivity and specificity without correlation
FibroTest	17	0.32-0.53	0.68	0.58-0.77	0.72	0.70-0.77	Bivariate random-effects model with correlation between sensitivity and specificity
FibroTest (low cut-off)	7	0.1-0.3	0.91	0.86-0.94	0.41	0.37-0.46	Random-effects model for sensitivity and specificity without correlation
Fibrotest (high cutoff)	10	0.6-0.7	0.57	0.46-0.67	0.85	0.74-0.92	Bivariate random-effects model with correlation between sensitivity and specificity
Imaging modalities							
ARFI	3	1.21-1.34	0.79	0.75-0.83	0.89	0.84-0.93	Fixed-effects model for sensitivity and specificity without correlation
MRE	3	—	0.94	0.13-1	0.92	0.72-0.98	Model 3; random effects for sensitivity and fixed effect for specificity
PLT_spleen ratio	3	1750-2200	0.88	0.62-0.99	0.73	0.41-0.99	Bivariate random-effects model with correlation between sensitivity and specificity
FibroScan	37	5.2-10.1	0.79	0.74-0.84	0.83	0.77-0.88	Bivariate random-effects model with correlation between sensitivity and specificity
US	3	—	0.35	0.14-0.63	0.86	0.59-0.96	Metadas
US_SAPI	3	—	0.74	0.69-0.79	0.79	0.72-0.85	Model 5; fixed-effect model for both
US_SAPI (high cutoff)	2	—	0.61	0.54-0.68	0.96	0.9-0.98	Model 5; fixed-effect model for both
US_SAPI_F2 (low cutoff)	2	—	0.94	0.9-0.97	0.39	0.31-0.49	Model 5; fixed-effect model for both
Combination of fibrosis noninvasive tests algorithms							
Bordeaux	1	—	0.88	0.85-0.91	0.89	0.85-0.92	Single study
Fibropaca	1	—	0.85	0.81-0.89	0.90	0.86-0.93	Single study
Leroy	1	—	0.90	0.79-0.96	0.98	0.95-0.99	Single study
SAFE	4	—	1.00	1.00-1.00	0.81	0.80-0.83	Fixed-effects model for sensitivity and specificity without correlation

Bordeaux consists of the synchronous use of FibroTest and FibroScan, followed by liver biopsy in cases of discordance. Fibropaca consists of the synchronous use of FibroTest plus APRI and/or Forns, followed by liver biopsy in cases of discordance. Leroy consists of the synchronous use of FibroTest plus APRI, followed by liver biopsy in patients with intermediate values. SAFE is a sequential algorithm that consists of APRI as the initial test followed by FibroTest in the indeterminate fibrosis cases or liver biopsy in patients with low risk of fibrosis according to APRI.

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; GLUCI, Göteborg University Cirrhosis Index; MP3 score, combination of PIIINP and MMP-1; PIIINP, N-terminal procollagen III; MMP-1, matrix metalloproteinase 1; YKL-40, human cartilage glycoprotein 39; ELF, enhanced liver fibrosis score; ARFI, acoustic radiation force impulse; PLT\_spleen ratio, platelet to spleen size ratio; US, ultrasound; US\_SAPI, ultrasonographic evaluation of the splenic artery pulsatility index; CI, confidence interval.

in the Supporting Information) shows the increase in the ICER for treat all as the assumption around treatment benefit for this group of patients is relaxed.

**Secondary Analysis.** Using only those 14 NITs where the bivariate model for the meta-analysis converged did not change the overall result, and treat all remained cost-effective with an ICER of £8,162.

**Exploratory Analyses.** The exploratory analysis to assess the possible effect on results of increased costs and effectiveness associated with treatment with Peg-

IFN- $\alpha$ -2a, RBV, and SOF found that the base-case analysis results remained the same and treat all was still the most cost-effective strategy to adopt, compared to no treatment or only treating patients  $\geq$ F2 with Peg-IFN- $\alpha$ -2a, RBV, and SOF (genotypes 1 and 4) or RBV and SOF (genotypes 2 and 3), though with a higher ICER of £16,028 (full table in the Web Appendix in the Supporting Information).

The exploratory analysis on new treatments found that if SVR rates were 90% for genotypes 1 and 4 and

**Table 4. Base-Case Analysis\***

Test Strategy	Costs (£)	QALYs	Incremental Cost (£)	Incremental QALYs	ICER (£)
(S4) type IV collagen and PLT spleen	46,911	14.22	–	–	–
FibroSpect and FibroScan	46,954	14.27	43	0.05	928
Treat all	51,241	14.73	4,287	0.47	9,204

\*Second stage of the analysis: comparison of sequential testing strategies, most cost-effective tests from first stage of the analysis, liver biopsy, published algorithms, NIT with a combined cut-off diagnostic threshold, and the treat all and no treatment comparators.

Abbreviation: PLT, platelet.

costs increased by £20,000 for all genotypes, the base-line results do not change substantially, with the treat all strategy remaining the most cost-effective strategy with an ICER of £10,009. However, increasing the additional cost by £40,000 increases the ICER for the treat all strategy to £21,174, which would not be cost-effective given a £20,000 threshold. The most cost-effective option in this case would be testing with magnetic resonance elastography (MRE) and treating those patients with  $\geq$ F2, with an ICER of £9,189. The incremental treatment cost threshold for the treat all strategy to remain the most cost-effective strategy was determined at £37,500.

**Discussion**

The results of our economic modeling and analysis indicate that a treat all strategy with currently available drugs is the most cost-effective strategy in patients with CHC in the UK. Given the similar health costs

and treatment pathways for CHC in Western countries, it is reasonable to extrapolate that this holds true for most countries in the developed world.

Our meta-analysis of NITs has been the most detailed and extensive to date, including all described serum tests and imaging modalities with no language restrictions and using state-of-the-art statistical and reporting methods. A recent systematic review only included serum tests and did not report on summary sensitivity and specificity, but chose to present median values.<sup>22</sup> A striking finding of our meta-analysis was that the vast majority of studies (98%) had high risk of bias and failed in important methodological aspects, such as the absence of predetermined test cutoffs and suboptimal quality of liver biopsy as the reference standard. NITs performed significantly better for the diagnosis of cirrhosis than for lesser fibrosis stages. Indirect serum NITs, such as APRI and FIB-4, fail to classify a significant proportion of patients who fall into the gray zone of indeterminate values. Proprietary




Fig. 2. CEAFs showing the probability that treat all is cost-effective, compared to alternatives over a range of values for the maximum acceptable cost-effectiveness threshold value (ceiling ratio  $\lambda$ ) for HCV. PLT\_Spleen, platelet/spleen size ratio.

serum NITs, with the possible exception of FibroTest, are insufficiently validated in independent cohorts. The increasingly used FibroScan does not have validated cutoffs for specific fibrosis stages.<sup>23</sup> Therefore, NITs need better-quality studies and further validation, particularly for the diagnosis of moderate fibrosis.

Our economic analysis revealed that treating all CHC patients without testing for fibrosis stage was the most cost-effective strategy given a cost-effectiveness threshold of £20,000. This result was robust to most of the amendments in the sensitivity analysis. A key driver in the cost-effectiveness results is that patients with mild fibrosis (F0-F1) gain benefit from treatment, albeit at an increased cost. We have performed a threshold analysis to confirm this assumption. For the treat all strategy to cease to be cost-effective, the relative treatment benefit would need to be reduced by only 23%. In addition to mortality and morbidity associated with liver disease, the analysis reflects the risk of death from other causes. This was based on estimates from the UK general population; however, we recognize that, in practice, some patients with CHC may have higher mortality rates. This is likely to underestimate the ICER for the treat all strategy, relative to the comparators.

Previously published models by Wright et al.<sup>9</sup> and Liu et al.<sup>8</sup> evaluated the cost-effectiveness of alternative treatments for CHC. The results from both studies show that treating all patients irrespective of fibrosis level is cost-effective at UK cost-effectiveness thresholds. The analysis by Wright et al. evaluated early treatment for patients with CHC (all nongenotype 1 patients grouped together). The study by Liu et al. evaluated different treatment strategies, which included the use of an NIT (FibroTest) in genotype 1-3 patients, but did not incorporate its diagnostic accuracy. This model also assumed a linear progression from F0 to the F4 health state and assumed that the costs for the F0-F4 health states were the same. Our study adds substantially to both of these studies. We evaluated more treatments than Wright et al. (IFN- $\alpha$  and RBV and Peg-IFN in a sensitivity analysis) and Liu et al. (Peg-IFN- $\alpha$ , RBV, and TVR) and also performed exploratory analyses for more-potent antiviral treatments. Our model incorporated data on differential rates of disease progression and costs according to different health states. Most important, we evaluated 57 NITs for use in patients with genotype 1-4 CHC and incorporated their diagnostic accuracy and the consequences of TP, FP, FN, and TN results in the Markov model. This makes our approach unique and distinct from previous models.

New antiviral treatments with increased efficacy and lesser side effects for genotypes 1 and 4 will soon be licensed.<sup>21</sup> However, the cost-effectiveness of such drugs will depend on their price and robust data on effectiveness. The exploratory analysis presented here shows that a strategy of treat all with Peg-IFN- $\alpha$ -2a, RBV, and SOF would be cost-effective, compared to no treatment or using the NITs to restrict that treatment combination to patients with  $\geq$ F2. Given that other treatment combinations are available, the cost-effectiveness of SOF needs to be assessed, relative to currently standard treatments. The exploratory analysis on other treatments showed that treat all would be cost-effective if the overall increase in treatment costs is up to approximately £37,500, but not above. In the latter case, a strategy of NIT and treatment of patients with  $\geq$ F2 is the most cost-effective strategy. This is of particular importance, because the pricing of new antiviral therapies is not yet known and relative effectiveness is not fully established. Although the estimates on diagnostic accuracy of NITs carry a high risk of bias, our data indicate that if treatment costs increase beyond a certain point, then testing with NITs of a defined sensitivity, specificity, and cost will be the most cost-effective strategy.

Our economic modeling was performed from the perspective of an economy of a developed country, and therefore its findings cannot be extrapolated to the developing world. This would require a separate analysis with the use of different utilities and costs, such as the one recently performed in Egypt.<sup>24</sup> The emergence of population screening strategies for HCV infection, as recently recommended in the United States,<sup>25</sup> will result in further increases in health care costs. If the detection rates increase significantly, even cost-effective strategies might not be realistic in certain health care systems. We assumed that NITs used sequentially were independent of one another. Although this assumption did not influence the results, it has not been sufficiently tested. We have based the model on SVR being a valid surrogate outcome and that there are no long-term adverse events related to protease inhibitors as in previous economic models.<sup>26</sup> Our conclusions will change if the above is not true.

In conclusion, we have shown that treating all adult patients with CHC, irrespective of fibrosis stage, is the most cost-effective strategy with current standard treatments in developed countries. Licensing of more-potent and expensive antiviral treatment, such as SOF, does appear to be cost-effective given the current price; however, more costly combinations could change these findings. Further analyses of such treatments are

required to determine their cost-effectiveness. Because studies of NITs had a high risk of bias, better-quality data are urgently needed to validate their reported diagnostic accuracy.

## References

- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349:825-832.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol* 2011;55:245-264.
- Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. *N Engl J Med* 2009;360:1902-1906.
- Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. *HEPATOLOGY* 2011;53:325-335.
- Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-536.
- Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol* 2005;58:982-990.
- Takwoingi Y, Deeks JJ. MetaDAS: a SAS macro for meta-analysis of diagnostic accuracy studies. USER Guide Version 1.3. Available from: [http://srdtacochraneorg/sites/srdtacochraneorg/files/uploads/MetaDAS\\_Readme\\_v13\\_May\\_2012.pdf](http://srdtacochraneorg/sites/srdtacochraneorg/files/uploads/MetaDAS_Readme_v13_May_2012.pdf). Accessed October 25, 2012.
- Liu S, Schwarzingler M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. *PLoS ONE* 2011;6:e26783.
- Wright M, Grieve R, Roberts J, Main J, Thomas HC, Alexander G, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation. *Health Technol Assess* 2006;10:iii-93.
- van der Meer AJ, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. *Gut* 2014 May 9. doi: 10.1136/gutjnl-2013-305357. [Epub ahead of print].
- National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2013.
- National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. In: NICE Technology Appraisal Guidance 106. London: NICE; 2007.
- National Institute for Health and Clinical Excellence (NICE). Boceprevir for the treatment of genotype 1 chronic hepatitis C. In: Technology Appraisal Guidance 253. London: NICE; 2012.
- National Institute for Health and Clinical Excellence (NICE). Telaprevir for the treatment of genotype 1 chronic hepatitis C. In: NICE Technology Appraisal Guidance 252: NICE; 2012.
- National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. In: Part Review of NICE Technology Appraisal Guidance 75 and 106. London: NICE; 2010.
- Brooks R. EuroQol: the current state of play. *Health Policy* 1996;37:53-72.
- Longworth L, Young T, Buxton MJ, Ratcliffe J, Neuberger J, Burroughs A, Bryan S. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. *Liver Transpl* 2003;9:1295-1307.
- Drummond M, O'Brien BJ, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford, UK: Oxford University Press, 1997.
- Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. *Health Econ* 2001;10:779-787.
- Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon  $\alpha$ -2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. *Health Technol Assess* 2004;8:iii-iv, 1-125.
- Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med* 2013;368:1878-1887.
- Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. *Ann Intern Med* 2013;158:807-820.
- Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. *J Hepatol* 2011;54:650-659.
- Deuffic-Burban S, Schwarzingler M, Mallet V, Pol S, Pageaux GP, Canva-Delcambre V, et al. Immediate or delayed treatment initiation with "Previr" containing regimens in HCV-infected naive genotype 1 (G1) patients without severe fibrosis? A cost effectiveness analysis (ANRS No 12188). *J Hepatol* 2013;58(Suppl. 1):S331.
- Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. *Ann Intern Med* 2012;157:817-822.
- van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? *J Hepatol* 2014;60:191-196.
- Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. *Health Technol Assess* 2006;10:1-113, iii.
- Fried MW, Shiffman ML, Rajender Reddy K, Smith C, Marinos G, Gonçales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975-982.
- Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. *Gut* 2006;55:1350-1359.
- Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon  $\alpha$ -2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. *Gut* 2005;54:858-866.
- Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. *Int J Technol Assess Health Care* 2009;25:171-180.

## Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website.